Immunovant, Inc. (IMVT)
About Immunovant, Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$505.6M
- Total assets
- $957.0M
- Market cap
- $6.4B
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Operating expenses
- $532.9M
- Income tax
- $215.0K
- Net income
- -$505.6M
- EPS (basic)
- $-2.77
- EPS (diluted)
- $-2.77
Balance sheet
- Total assets
- $957.0M
- Current assets
- $948.8M
- Total liabilities
- $104.4M
- Current liabilities
- $104.4M
- Shareholders’ equity
- $852.6M
Cash flow
- Operating cash flow
- -$407.3M
- Investing cash flow
- -$8.0K
- Financing cash flow
- $595.8M
- Net cash flow
- $188.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $6.4B
- EPS (diluted)
- $-2.77
- Shares outstanding
- 162.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 21, 2019
Immunovant, Inc. (IMVT) Stock Price
- Reported a net loss of $505.6M.
- Trading 4% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Immunovant, Inc..
Write a review
News about Immunovant, Inc.
News & sentiment via Polygon.io
Immunovant, Inc.: frequently asked questions
Is Immunovant, Inc. an American company?
Immunovant, Inc. is a US-based company headquartered in Durham, North Carolina, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Immunovant, Inc. headquartered?
Immunovant, Inc. is headquartered in Durham, North Carolina, United States.
Is Immunovant, Inc. publicly traded?
Yes — Immunovant, Inc. is a publicly traded company. Its stock trades under the ticker symbol IMVT on the NASDAQ.
What does Immunovant, Inc. do?
Immunovant, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
